RPRX
Royalty Pharma plc Class A
stockNASDAQ
royalty pharma is the industry leader in acquiring revenue-producing intellectual property – principally royalty interests in marketed and late stage biopharmaceutical products with $13 billion in assets. since inception in 1996, royalty pharma and its predecessors have invested approximately $5.8 billion to assemble a leading portfolio of royalty interests in pharmaceutical and biopharmaceutical products. royalty pharma's strategy has been to acquire royalty interests in leading pharmaceutical and biotechnology products and hold these interests as part of a portfolio, seeking to diversify its revenue base across product and therapeutic classes. royalty pharma captures many of the strong and predictable aspects of the pharmaceutical industy while limiting the typical risks of biopharmaceutical companies. royalty pharma currently owns a diversified portfolio of royalty interests in several high- quality blockbuster biopharmaceutical products, including abbott's humira®, j&j/merck's remi
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 58.37 | 2026-09-28 | -2.11% | -0.945 |
| 1M | 63.96 | 2026-09-04 | -10.66% | 0.700 |
| 3M | 56.92 | 2026-07-06 | +0.39% | 0.139 |
| 6M | 47.32 | 2026-04-06 | +20.75% | 0.146 |
| 1Y | 36.07 | 2025-10-03 | +58.41% | 0.260 |
| 2Y | 27.75 | 2024-10-04 | +105.91% | — |
| 5Y | 35.17 | 2021-10-04 | +62.47% | 0.444 |
Royalty Pharma plc Class A (NASDAQ:RPRX) stock price today is $57.14, and today's volume is 2,229,485. RPRX is down 0.850% today. The 30 day average volume is 3.00M. RPRX market cap is $25.44B with 445.28M shares outstanding.